Pharma News

Povorcitinib by Incyte for Hidradenitis Suppurativa: Likelihood of Approval

Povorcitinib is under clinical development by Incyte and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III drugs for Hidradenitis Suppurativa have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Povorcitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Povorcitinib overview

Povorcitinib (INCB-54707) is under development for the treatment of prurigo nodularis, hidradenitis suppurativa and nonsegmental vitiligo. The drug candidate is administered through oral route in the form of tablet. It acts by targeting Janus kinase 1 (JAK1).

Incyte overview

Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

For a complete picture of Povorcitinib’s drug-specific PTSR and LoA scores, buy the report here.




Source link
#Povorcitinib #Incyte #Hidradenitis #Suppurativa #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *